Russia to provide subsidies to manufacturers of innovative drugs
The Russian government has officially approved the provision of subsidies to both domestic and foreign drugmakers that are involved in the production of innovative drugs, according to recent statements, made by some leading local analysts in the field of pharmaceutics and some Russian media reports.
This has been confirmed by the Russian Minister of Industry and Trade, Denis Manturov, who said the new subsidies will cover a significant part of manufacturers' expenses “from the R&D stage and clinical trials to commercial production, and is part of the existing state "Development of pharmaceutical and medical industries in Russia" program.
The Minister added that recipients of these subsidies will be determined as part of competitive procedures that will be conducted by the state, with the aim of evaluating the level of innovation that is used by drugmakers in their manufacturing processes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze